We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Elevated Levels of Two Protein Biomarkers Indicate Potential for Development of Pre-Eclampsia

By LabMedica International staff writers
Posted on 16 Jul 2020
Print article
Image: Summary of changes FKBPL and CD44 changes throughout gestation in pregnancies complicated by pre-eclampsia (Photo courtesy of Oxford Press)
Image: Summary of changes FKBPL and CD44 changes throughout gestation in pregnancies complicated by pre-eclampsia (Photo courtesy of Oxford Press)
A pair of novel protein biomarkers has been identified in the blood of asymptomatic pregnant women that can be used to predict the potential onset of pre-eclampsia.

Pre-eclampsia (PE) is a disorder of pregnancy characterized by the onset of high blood pressure and often a significant amount of protein in the urine. When it arises, the condition begins after 20 weeks of pregnancy. In severe disease there may be red blood cell breakdown, a low blood platelet count, impaired liver function, kidney dysfunction, swelling, shortness of breath due to fluid in the lungs, or visual disturbances. Pre-eclampsia increases the risk of poor outcomes for both the mother and the baby. If left untreated, it may result in seizures at which point it is known as eclampsia. Ten to 15% of maternal mortality is associated with pre-eclampsia and eclampsia.

Development of effective prevention and treatment strategies for pre-eclampsia has been limited by the lack of accurate methods for identification of at-risk pregnancies.

In an effort to correct this lack, investigators at the University of Technology Sydney (Australia) evaluated the diagnostic and therapeutic potential for pre-eclampsia of the angiogenesis protein markers, FKBPL-CD44. FKBPL (FKBP prolyl isomerase like) has similarity to the immunophilin protein family, which play a role in immunoregulation and basic cellular processes involving protein folding and trafficking. CD44 is a cell-surface glycoprotein involved in cell-cell interactions, cell adhesion, and migration. It is a receptor for hyaluronic acid (HA) and can also interact with other ligands, such as osteopontin, collagens, and matrix metalloproteinases (MMPs). This protein participates in a wide variety of cellular functions including lymphocyte activation, recirculation and homing, hematopoiesis, and tumor metastasis.

For the current study, the investigators analyzed 57 samples that were pre-diagnosis (15 and 20 weeks’ gestation) and 18 that were post-diagnosis (14 for plasma; four for placenta) of pre-eclampsia for determination of FKBPL and CD44 concentrations, compared to healthy controls.

Results revealed that the CD44/FKBPL ratio was reduced in placenta and plasma following clinical diagnosis of pre-eclampsia. At 20 weeks’ gestation, a high plasma CD44/FKBPL ratio was independently associated with the 2.5-fold increased risk of pre-eclampsia.

"There are two main types of pre-eclampsia: early-onset pre-eclampsia diagnosed before 34 weeks of a pregnancy and late-onset pre-eclampsia diagnosed from 34 weeks onwards," said senior author Dr. Lana McClements, lecturer in biotechnology at the University of Technology Sydney. "The vast majority of the current screening and monitoring strategies are focused on early-onset pre-eclampsia, which comprises only 10-15% of all pre-eclampsia cases, whereas late pre-eclampsia has been largely neglected."

"The biomarkers allow the prediction of irregular placenta or maternal vascular function, which are key underlying causes of pre-eclampsia," said Dr. McClements. "This could lead to the early diagnosis and prevention of severe pre-eclampsia and associated complications including death, therefore also giving insight into disease mechanisms and possible treatment targets."

The study was published in the July 3, 2020, online edition of the Journal of Clinical Endocrinology and Metabolism.

Related Links:
University of Technology Sydney

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.